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Summary 
Objective: The aim of this study was to describe the physiological activity of the myometrium in 
oestrus and dioestrus and the induced activity after medication in cows with particular reference 
to segmental differences. Material and methods: Six cows were given the pharmaceuticals 
carbetocin, oxytocin and prostaglandin F2α (dinoprost) intramuscularly and prostaglandin E2 
intravenously. The physiological myometrial activity was recorded for 15 minutes and the 
induced activity for 105 minutes by using a transcervically attached pressure probe containing 
six pressure microtransducers. Results: Lower pressures were measured in dioestrus 
compared to oestrus before (dioestrus 3.2 ± 8.88 mmHg, oestrus 12.4 ± 13.23 mmHg, 
p < 0.0001) and after the drug administration. Carbetocin provoked the longest lasting effect 
(60 minutes in dioestrus, 75 minutes in oestrus) followed by prostaglandin E2 (45 minutes in 
dioestrus, 60 minutes in oestrus), prostaglandin F2α (30 minutes each) and oxytocin (15 
minutes in oestrus only). In contrast to the other drugs carbetocin did not cause any pressure 
decrease beneath the base level after the primary pressure increase in dioestrus. In dioestrus 
the pressure before drug administration was significantly higher in the cervix 
(3.6 ± 19.40 mmHg) and the uterine body (7.1 ± 36.10 mmHg) than in the uterine horn 
(1.1 ± 7.21 mmHg). Conversely, in oestrus the pressure in the uterine horn 
(16.6 ± 17.73 mmHg) was significantly higher than in the uterine body (6.2 ± 16.59 mmHg) and 
the cervix (10.4 ± 17.91 mmHg). Drug administration in dioestrus caused a cornual pressure 
increase and the pressure in the uterine body decreased, whereas in oestrus the pressure 
increased in all uterine segments. The physiological frequency of the pressure waves in 
dioestrus was 5.2 ± 3.02 in 15 minutes compared to 7.5 ± 2.89 in 15 minutes in oestrus. No 
traceable changes of the contraction frequency were found after medication. Conclusion and 
clinical relevance: Carbetocin caused the most enduring increase in intrauterine pressure in 
dioestrus and oestrus and may therefore be indicated best for therapeutic use. The tested 
drugs had the same effects on the various uterine segments and no effect on the contraction 
frequency. 
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Zusammenfassung 
Gegenstand und Ziel: Untersuchung der physiologischen und induzierten myometralen 
Aktivität nach Medikamentengabe bei Kühen unter besonderer Berücksichtigung segmentaler 
Unterschiede in den Zyklusstadien Östrus und Diöstrus. Material und Methoden: Sechs 
Kühen wurden die Wirkstoffe Carbetocin, Oxytocin und Prostaglandin F2α (Dinoprost) 
intramuskulär sowie Prostaglandin E2 intravenös appliziert. Mittels einer transzervikal 
eingebrachten Druckmesssonde mit sechs Messpunkten wurde die physiologische Motorik 
über 15 Minuten und die induzierte Motorik ber 105 Minuten aufgezeichnet. Ergebnisse: Im 
Diöstrus ergaben sich sowohl vor als auch nach Medikamentengabe in allen Fällen niedrigere 
Drücke als im Östrus (Diöstrus 3,2 ± 8,88 mmHg, Östrus 12,4 ± 13,23 mmHg, p < 0,0001). 
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Carbetocin zeigte die am längsten messbare Wirkung (60 Minuten im Diöstrus, 75 Minuten im 
Östrus), gefolgt von Prostaglandin E2 (45 Minuten im Diöstrus, 60 Minuten im Östrus), 
Prostaglandin F2α (je 30 Minuten) und Oxytocin (15 Minuten nur im Östrus). Zudem bewirkte 
Carbetocin im Diöstrus im Gegensatz zu den anderen Wirkstoffen nach dem primären 
Druckanstieg keinen Druckabfall unter das Ausgangsniveau. Vor der Medikation war der Druck 
im Diöstrus in der Zervix (3,6 ± 19,40 mmHg) und im Uteruskörper (7,1 ± 36,10 mmHg) 
signifikant höher als im Uterushorn (1,1 ± 7,21 mmHg). Im Östrus hingegen lag der Druck im 
Uterushorn (16,6 ± 17,73 mmHg) signifikant höher als im Uteruskörper (6,2 ± 16,59 mmHg) 
und in der Zervix (10,4 ± 17,91 mmHg). Die Medikamentengabe bewirkte im Diöstrus einen 
Druckanstieg in den Uterushörnern und einen Druckabfall im Uteruskörper, während im Östrus 
der Druck in allen Segmenten anstieg. Die physiologische Frequenz der Kontraktionswellen 
war im Diöstrus mit 5,2 ± 3,02 in 15 Minuten niedriger als im Östrus mit 7,5 ± 2,89 in 15 
Minuten. Nach der Medikation kam es zu keiner nachvollziehbaren Änderung der 
Kontraktionsfrequenz. Schlussfolgerung und klinische Relevanz: Carbetocin bewirkte in 
beiden Zyklusstadien den am längsten anhaltenden intrauterinen Druckanstieg und scheint 
daher am geeignetsten für eine therapeutische Anwendung. Die verwendeten Uterotonika 
unterschieden sich nicht in ihrer Wirkung auf die verschiedenen Uterussegmente und hatten 
keinen Einfluss auf die Kontraktionsfrequenz. 
Correspondence to 
Prof. Dr. U. Bleul 
Clinic of Reproductive Medicine, Department of Farm Animals 
Vetsuisse-Faculty, University Zurich 
Winterthurerstrasse 260 
8057 Zurich, Switzerland 
Email: ubleul@vetclinics.uzh.ch 
Uterusdruckmessungen beim Rind unter Einfluss von Carbetocin, Oxytocin sowie 
Prostaglandin E2 und F2α 
Tierärztl Prax 2015; 43 (G): 
http://dx.doi.org/10.15653/TPG-140341 
Received: April 16, 2014 
Accepted after revision: September 26, 2014 
Epub ahead of print: 
Introduction 
The coordinated muscle activity of the bovine uterus has several important functions in 
reproductive events during oestrus, pregnancy, parturition and the puerperal period when the 
placenta, lochia or pathological uterine contents are expelled. In general terms, the uterine 
body and horns have a transport function and the uterine cervix serves as a barrier. Several 
studies evaluated the effect of various uterotonic drugs in relation to these functions because of 
considerable interest in their therapeutic use (2, 4, 6, 9, 14–17, 19, 27, 29, 30, 34). 
Microtransducers represent the most advanced method to measure intrauterine pressure in 
veterinary medicine. The well-established technique has been used in former studies using one 
(34), two (28–30) or three (15–17, 19) microtransducers in a pressure probe. 
Oxytocin and its synthetic analogue carbetocin increased the frequency of uterine 
contractions for 2 hours and the total area under the curve for intrauterine pressure for 1 hour in 
cows (6). Oxytocin, a peptide hormone, is produced in the hypothalamus and secreted by the 
pituitary gland. It is also produced and secreted by the corpus luteum. In circulation it has a 
half-life of 1–8 minutes. Oxytocin causes the smooth musculature of the female genital tract 
and mammary gland to contract (5). The uterine effect of the hormone is a function of the 
oxytocin receptor concentration in endometrium and myometrium having its peak in oestrus 
and its lowest concentration around day 9 of the cycle (5, 13, 22). These differences were also 
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described in the cervix (13). Carbetocin has the same general properties but because of its 
greater stability its half-life is much longer with up to 6 hours (5). 
Another study investigated the uterotonic effects of different prostaglandins in cattle (19). 
Prostaglandin E2 (PGE2) is an inflammatory mediator, protects the gastric mucosa and controls 
reproductive events. It is of ovarian and endometrial origin and together with other factors is 
involved in the process of ovulation. It also causes an increase in intracellular calcium 
concentration and thus activates uterine muscle contractions (5, 37). Prostaglandin E2 
enhanced uterine motility for up to 45 minutes in cattle and shortened the duration of parturition 
(17, 19, 21, 29). A PGE2 “relaxant” receptor (EP2) was described, which is expressed in 
endometrium and myometrium during the estrous cycle with a peak between day 10 and day 
18 (3). EP2 is upregulated in early pregnancy, presumably to induce uterine quiescence. This 
was also shown in late pregnany and parturition, indicating that an upregulation of contractile 
factors overcomes the inhibitory effects of EP2 at parturition (35). In women, PGE2 causes 
uterine contraction and cervical relaxation (10, 31). 
Prostaglandin F2α (PGF2α), another inflammatory mediator, is synthesised in the 
endometrium towards the end of the luteal phase and causes luteolysis. It is responsible for 
increased uterine motility via an increase in intracellular calcium concentration. The first plasma 
metabolite of PGF2α is 15-keto-13,14-dihydro-PGF2α, which has a half-life of 3–8 minutes (5). 
The effect of PGF2α and its analogues on the myometrium generally consists of increased 
muscular activity; however, this effect does not occur with all analogues and not at every cycle 
stage (17, 19, 27, 29, 34). This led to the conclusion that the stimulating effect of PGF2α on the 
uterine muscle is contingent on the type of analogue but also on the stage of the oestrous cycle 
(34). The latter might be a result of changes in the concentration of the “contractile” PGF2α 
receptor (FP) during the oestrous cycle. It has been shown, that the amount of FP is rising from 
late term gestation to parturition (35). In addition to its direct uterotonic effect, the ability of 
PGF2α to cause luteolysis (5) results in a greater intrauterine pressure during the following 
oestrus (2, 9, 18, 27, 28, 32) facilitating the expulsion of uterine content. This represents a 
secondary therapeutic effect, e. g. in case of endometritis. 
The hypothesis of this study was that oxytocin, carbetocin, PGE2 and PGF2α cause an 
increase in uterine tone that can be quantified in different segments of the uterus. Qualitative 
and quantitative differences between the effects of the tested drugs should provide an 
indication of the therapeutic usefulness, e. g. the evacuation of the uterus in case of an 
endometritis. Therefore the goal was to measure the strength and duration of intrauterine 
pressure before and after treatment with uterotonic drugs using a microchip precision pressure 
catheter with six semi-conductor pressure sensors. This kind of catheter, which has never 
before been used in a similar setting, makes it possible to measure the pressure in different 
uterine segments simultaneously and thereby comparable. A secondary goal was to investigate 
physiological differences in pressure between different uterine segments during oestrus and 
dioestrus. 
Material and methods 
Animals 
Six multiparous Swiss Braunvieh cows that were at least 8 weeks in milk and between 5 and 16 
years old from a university-owned research farm were used. The cows had to be assessed 
healthy in the clinical and gynaecological examinations before they were included in the 
experiment. 
Pressure catheter and fixation 
The pressure catheter was a Gastrobar® microchip precision pressure catheter with six semi-
conductor pressure sensors (microtransducers) custom-made for this study (Raumedic, 
Münchberg, Germany). The probe had an average diameter of 3.5 mm and the first pressure 
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sensor (P1) was 2 cm from the tip of the probe (Fig. 1). The remaining pressure sensors (P2 to 
P6) were located at 5-cm intervals so that the sixth sensor was 27 cm from the tip of the probe. 
The microchip precision pressure catheter was introduced into a uterine horn via a sheath 
(modified Detlef biopsy instrument reaching from the handle to the external cervical os; Fig. 1). 
After placement of the pressure catheter (A, green catheter visible in the opened uterine horn 
and at the caudal end of the sheath) a piece of plastic tubing (D, custom-made from the sheath 
of a swabbing instrument) with the same length as the sheath and with a slit along its entire 
length was clipped onto the catheter piece by piece and slid towards the cervix. The caudal end 
of the tubing rested against the two rings at the caudal end of the sheath, which was attached 
to the perineal tissue with an elastic band (not shown in Fig. 1). The tubing served to fix the 
pressure catheter in place. A 20-mm bulb attached to the tip of the stealth was lodged against 
the external cervical os by force of the elastic perineal attachment and kept the tube and 
catheter from entering the cervix. The premeasured position of the 77-cm mark of the pressure 
catheter at the caudal end of the catheter ensured that the most caudally located measuring 
point P6 was located 4 cm cranial to the bulb-end of the plastic tubing in the cervix. The 
pressure data were transmitted to an attached measuring unit (Ellipse, Andromeda, 
Taufkirchen/Potzham, Germany) and from there to a laptop. The software AUDACT 
(Andromeda) was used to store and analyse the data. 
Uterotonic drugs 
Experimental drugs included carbetocin (LongActon®, Vital, Switzerland), oxytocin 
(Physovetin®, Streuli Pharma, Switzerland), prostaglandin E2 (Dinoproston, Myoton E2®, 
Graeub, Switzerland) and prostaglandin F2α (Dinoprost, Dinolytic®, Zoetis, Switzerland). The 
dosages and routes of administration were chosen according to the manufacturers’ 
recommendations and were as follows: 30 IU for oxytocin, intramuscularly (i. m.); 0.35 mg for 
carbetocin, i. m.; 25 mg for prostaglandin F2α, i. m.; and 2.5 mg for prostaglandin E2 2.5 mg, 
intravenously into a jugular vein. The triceps muscle of the forearm was used for intramuscular 
injections. 
Determination of cycle stage 
To determine the cycle stage, the ovaries of the cows were examined transrectally once daily 
using B-mode sonography until ovulation was detected, which was defined as the first day that 
a follicle was no longer visible on the sonograms (day 0). After ovulation, the daily examinations 
were continued to verify the cycle stage. 
A corpus luteum with a diameter ≥ 23 mm combined with a plasma progesterone 
concentration > 1 ng/ml was defined as dioestrus (7, 8). A corpus luteum with a diameter 
< 23 mm combined with a plasma progesterone concentration ≤ 1 ng/ml and one or several 
follicles with a diameter ≥ 12 mm was defined as oestrus. 
For determination of plasma progesterone concentration, 10 ml blood was collected from a 
jugular vein into a lithium heparin tube (Sarstedt, Nümbrecht, Germany) and centrifuged. The 
harvested plasma was stored at –18 °C until analysis. Progesterone was measured at the 
Endocrinology Laboratory at the Clinic for Obstetrics, Gynaecology and Andrology for Large 
and Small Animals and Ambulatory Field Service, Justus-Liebig-University, Giessen, Germany 
using a radioimmunoassay (24). 
Study design 
Each of the six cows underwent one pressure measurement with each of the four experimental 
drugs during oestrus and during dioestrus for a total of 48 measurements. Oxytocin or 
carbetocin were tested on day 10 and PGE2 or PGF2α after a wash-out period of 48 hours 
(day 12) of the same cycle. Oxytocin or carbetocin was then tested on the first day of the next 
oestrus, and PGE2 or PGF2α after a wash-out period of 24 hours to ensure that both 
measurements were carried out during the same oestrus. The same course of measurements 
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was done starting with the second peptide hormone (oxytocin or carbetocin) and the second 
prostaglandin (PGE2 or PGF2α). 
Pressure measurement procedure 
The pressure catheter was calibrated to barometric pressure and set to 0 before intrauterine 
placement. The cows were allowed 20 minutes to adapt to the catheter. At the beginning of 
every measurement (four in dioestrus and four in oestrus per cow), recordings of the 
physiological uterine pressure were carried out for 15 minutes (baseline measurement). The 
test drug was then given and the pressure recorded for another 105 minutes. Measuring 
artefacts defined as impacts on the pressure sensors that were not related to changes in 
myometrial tone such as urination, defecation, coughing, vocalisation or straining to expel air 
from the vagina were noted. 
Side effects 
Heart and respiratory rates and possible side effects were recorded before the start of the 
experiment, 10 minutes after the start of pressure recordings and 5, 30, 60 and 120 minutes 
after administration of the test drug. 
Data processing 
Each measuring point of the pressure catheter yielded data sets with 20 pressure readings per 
second. These data sets were transferred to an Excel spread sheet (Microsoft, Wallisellen, 
Switzerland) and means were calculated for a 15-minute period (minutes 15–29, referred to as 
baseline) before and seven 15-minute periods (minutes 31–45, 46–60, 61–75 etc.) after drug 
administration. The readings from the six measuring points were used for comparison of the 
pressure in different uterine segments, and the means of all six measuring points were used for 
comparison of the overall pressure. In case of artefacts, a software program (AUDACT, 
Andromeda) was used to delimit and eliminate the affected recordings, and the means were 
calculated for the remaining data of the respective 15-minute period. 
Endpoints 
Oestrous cycle-related changes in overall uterine pressure were analysed using the means of 
the eight time periods during oestrus and dioestrus for all drugs combined. 
Differences in pressure between individual measuring points were analysed for all eight time 
periods during dioestrus and oestrus for all drugs combined. Differences in pressure between 
individual measuring points were analysed during oestrus and dioestrus for each drug by 
comparing time periods 1 and 3. Time period 3 (i. e., the second after medication) was 
associated with the greatest pressure increase for all pressure points. 
The duration of effect of each drug was determined during dioestrus and oestrus by 
comparing the mean overall pressure during time period 1 with the pressures during time 
periods 2 to 8. This allowed determination of the duration of effect for each drug with an 
accuracy of 15 minutes. 
Statistics 
The mean uterine pressures recorded at the eight measuring periods were analysed using 
StatView Version 5.0 (SAS Institute, Cary, USA). The Shapiro-Wilk test was employed to test 
the data for normal distribution. Because all data were normally distributed, they were reported 
as mean ± standard deviation. Including the individual differences in the statistical models 
differences in pressure between time periods were analysed for both cycle stages separately or 
combined for each drug using a paired t-test. 
Student’s t-test for paired samples was used to analyse differences in mean overall pressure 
at all time periods between oestrus and dioestrus for each drug separately and for all drugs 
combined, to analyse differences in mean pressure at the individual measuring points and in 
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each time period for all drugs and both cycle stages combined and to analyse differences in 
mean pressure recorded at the different measuring points between time periods 1 and 3. A p-
value ≤ 0.05 was considered significant. 
This study was approved by the Committee for the Permission of Animal Experimentation of 
the Canton of Zurich (04/2007). 
Results 
Plasma progesterone concentration 
The mean progesterone concentration of the cows diagnosed sonographically as oestrous was 
0.59 ± 1.13 ng/ml. With one exception the plasma progesterone concentrations were < 1 ng/ml 
and were in agreement with clinical and sonographic findings. The exception was a cow with a 
progesterone concentration > 1 ng/ml in a repeated assay, accompanied by a corpus luteum 
measuring 22 mm in diameter and a dominant follicle that was no longer visible the next day. 
The measurements on this test day were therefore included for calculation of the mean for the 
cows in oestrus. 
In two cows, no blood was collected when they were tested in oestrus. The mean 
progesterone concentration of the cows diagnosed clinically and sonographically as dioestrous 
was 5.45 ± 1.34 ng/ml. 
Side effects 
Adverse signs such as colic were not seen, which indicated that the wellbeing of the cows was 
not affected by the measuring equipment. Some cows reacted with defensive movements 
during drug administration and insertion of the pressure catheter, but these reactions subsided 
during the adaption period. Three of the six cows were dripping milk a few minutes after 
oxytocin and carbetocin administration during oestrus and dioestrus. 
Pressure differences 
Cycle stage-related pressure differences 
The mean overall pressure was greater during oestrus than during dioestrus in each time 
period for all drugs combined (all p < 0.001, Fig. 2). The absolute differences in pressure before 
and after administration of the 4 drugs were significantly greater during oestrus than during 
dioestrus (all p < 0.001). 
Segmental pressure differences before medication 
Intrauterine pressures for all drugs combined in the six uterine segments before and after 
medication are shown in Table 1. In dioestrus, the mean pressure ranged from 
0.9 ± 8.63 mmHg at P4 to 7.1 ± 36.10 mmHg at P5 (Fig. 3). Pressures at P2, P5 and P6 were 
significantly greater than at the other measuring points except for P6 and P1, which were the 
same. In oestrus, the mean pressure ranged from 6.2 ± 16.59 mmHg at P5 to 
18.5 ± 17.12 mmHg at P2 (Fig. 4). Pressures at P2 and P3 were significantly greater than at 
the other measuring points. 
Segmental pressure differences after medication for all drugs combined 
In dioestrus, intrauterine pressure increased at P1 to P4 and decreased at P5 and P6 causing 
an intrauterine pressure gradient. With one exception, pressures at P1 to P4 were greater than 
those at P5 and P6 (Fig. 3). In oestrus, intrauterine pressure increased at all measuring points 
and the intrauterine pressure differences remained largely uniform; pressure at P2 and P3 was 
significantly greater than at the other measuring points. Pressures at P5 and P6 were uniform 
and, with three exceptions out of 12 measurements, significantly lower than at P1 and P4, 
which were in the intermediate pressure range (Fig. 4). 
The time periods 1 and 3 were compared to analyse the effect of medication on intrauterine 
pressure. In dioestrus, the pressure at P1 to P4 increased significantly after medication (all 
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p < 0.0001) and at P5 it decreased (p < 0.01). There was a numerical decrease at P6 (p = 
0.068, Fig. 5). In oestrus, the pressures at all measuring points increased significantly (Fig. 6). 
The greatest increase from 16.6 ± 17.73 mmHg to 27.6 ± 26.22 mmHg occurred at P3 
(p < 0.0001) and the smallest from 10.4 ± 17.91 mmHg to 12.5 ± 18.42 mmHg at P6 (p < 0.05). 
Segmental pressure differences after medication with individual drugs 
In dioestrus, carbetocin caused an increase in intrauterine pressure at P1 to P4 (all 
p < 0.0001) but not at P5 and P6. In oestrus, it caused an increase at P1 to P5 (P1 p < 0.05; 
P2–P5 p < 0.0001) but not at P6. 
In dioestrus, oxytocin caused an increase in intrauterine pressure at P1 to P4 (P1 p < 0.001; 
P2 p ≤ 0.05; P3 and P4 p < 0.0001) and a decrease in pressure from 14.5 ± 37.75 mmHg to –
2.1 ± 12.64 mmHg at P5 (p < 0.001) and from 6.0 ± 28.24 mmHg to –2.9 ± 8.79 mmHg at P6 
(p < 0.01). In oestrus, it caused an increase at P2 (p < 0.05) and P3 (p < 0.001). 
In dioestrus, prostaglandin E2 caused an increase in intrauterine pressure at P1, P3, P4 and 
P5 (all p < 0.0001). In oestrus, it caused an increase at P1 to P5 (P1, P3, P4 p < 0.0001; P2, 
P5 p < 0.01) and a numerical increase at P6 (p = 0.06). 
In dioestrus, prostaglandin F2α caused an increase in intrauterine pressure at P1 to P4 (P1, 
P2, P4 p < 0.0001; P3 p < 0.01) and a decrease from 23.7 ± 54.98 mmHg to 8.6 ± 24.97 mmHg 
at P5 (p < 0.001). At P6 there was a non-significant numerical decrease in pressure. In oestrus, 
PGF2α caused a significant increase in pressure from 7.3 ± 13.64 mmHg to 16.6 ± 17.41 mmHg 
at P1 (p < 0.0001). 
Duration of effect of the experimental drugs 
In dioestrus, carbetocin caused a significant increase in intrauterine pressure for 60 minutes 
and in oestrus for 75 minutes (Table 2). 
In dioestrus, oxytocin did not cause an increase in pressure; in the time periods 5–8 
(starting at minute 46 after medication) the pressure was significantly reduced compared to 
baseline. In oestrus, oxytocin caused a significant increase in pressure at the time period 3 and 
a numerical increase at time periods 2 and 4 (both p = 0.06; Table 2). 
In dioestrus, prostaglandin E2 caused a significant increase in intrauterine pressure for 45 
minutes (time periods 2–4). In time period 5, the pressure did not differ from baseline and in 
time periods 6–8, the pressure was significantly lower than baseline (all p < 0.0001). In oestrus, 
prostaglandin E2 caused a significant increase in pressure for 60 minutes (Table 2). 
In dioestrus and oestrus, prostaglandin F2α caused a significant increase in intrauterine 
pressure for 30 minutes (both p < 0.01). In dioestrus, this was followed by baseline pressure 
during time period 4 and decreased pressure during time periods 5–8 (p < 0.05). In oestrus, the 
pressure exceeded base line pressure again in time period 7 (p ≤ 0.05; Table 2). 
Discussion 
Cycle-stage related pressure differences 
Transport of semen from the cervix to the uterotubal junction constitutes a critical function of 
the bovine uterus during oestrus and thus, increased myometrial tone at this time of the 
oestrous cycle is expected, and was indeed confirmed in this study. The intrauterine pressure 
was greater in oestrus than in dioestus both before and after medication with four uterotonic 
drugs. This was in agreement with results of other studies in cows that showed greater 
intrauterine pressure amplitude during oestrus (2, 9, 18, 27, 28, 32). One of these studies also 
documented a greater area under the pressure curve, which was shown in vitro to be 
attributable mainly to the activity of the circular myometrial layer (18). During oestrus, the 
bovine uterus also had increased baseline pressure (28), longer duration of contractility (8, 14, 
31) and increased uterine activity expressed in Montevideo units (32). 
The reason for the differences in myometrial activity is the dominance of progesterone during 
dioestrus and the dominance of estradiol during oestrus (2, 36). Progesterone correlates 
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negatively with myometrial activity and estradiol correlates positively, which was demonstrated 
by exogenous administration of these hormones to ovariectomised cows (2). Estrogens 
increase the uterine endometrial and myometrial oxytocin receptor concentration in oestrous 
cows, whereas progesterone decreases the concentration (5, 13, 22). 
Segmental pressure differences 
This study revealed several significant pressure differences among various uterine segments 
both before and after medication with uterotonic drugs, which was in contrast to other studies 
that used pressure transducers with multiple miniature pressure sensors, but failed to record 
significant intersegmental differences (15–17, 19, 28). Segmental uterine pressure differences 
were measured in one older study (36) and isolated myometrial specimens from near the tip of 
the uterine horn had greater amplitudes and areas under the contractility curve than myometrial 
specimens from near the uterine body (23). This was in agreement with our findings that the 
lowest intrauterine pressures in dioestus were measured in the region of the uterine horn near 
the uterine body at P3 and P4. This finding combined with the greater pressure measured in 
the uterine body and cervix may be the reason for less efficient evacuation of pathological 
uterine content from the uterus during dioestrus compared with oestrus. During oestrus, 
maximum pressures were recorded in the middle of the horn at P2 and P3, intermediate 
pressures at P1 and P4 and the lowest pressure in the uterine body at P5. A similar decrease 
in intrauterine pressure from the horn towards the cervix was also recorded in an in-vitro study 
of bovine myometrial contractility (23). Such a pressure gradient should facilitate the transport 
of pathological uterine content towards the cervix. In contrast, a greater pressure was 
measured near the cervix than in the horn, which would impede uterine evacuation (36). 
Cervical pressure was considerably higher in oestrus than in dioestrus (10.4 ± 17.91 mmHg 
vs. 3.6 ± 19.40 mmHg). This appears counterintuitive because of the general expectations that 
the cervix facilitates the passage of semen in oestrus. However, compared with the uterine 
horn pressure, cervical pressure is lower in oestrus and higher in dioestrus. It appears therefore 
that sperm transport through the cervix is not governed solely by the absolute cervical pressure 
but by the pressure gradient in the entire uterus. 
All four tested drugs caused an increase in uterine horn pressure during dioestrus and 
oestrus. During dioestrus, cervical pressure decreased after oxytocin and PGF2α but did not 
change significantly after carbetocin and PGE2. During oestrus, none of the drugs affected 
cervical pressure significantly, which was surprising and contradictory with respect to PGE2. 
This hormone caused cervical relaxation in vitro in isolated specimens from the uterus of 
pregnant women and late-term guinea pigs (10, 11, 31). In cattle, PGE2 shortens the duration 
of labour and has been used for the removal of mummified foetuses (20, 21). 
Duration of effect of uterotonic drugs 
The duration of effect of all four drugs was longer in oestrus than in dioestrus. Carbetocin had 
the longest effect both in oestrus (75 minutes) and dioestrus (60 minutes) and was the only 
drug that did not result in a decrease in intrauterine pressure below baseline. The effect of 
carbetocin has not been evaluated during the oestrous cycle of cattle, but it increased 
intrauterine pressure for 1 hour, 14–16 hours postpartum (6). The duration of effect of 
carbetocin in the mare is longer compared with oxytocin (1). In myometrial specimens from 
late-term women, carbetocin and ocytocin caused similar increases in contractility (26), 
whereas in rats, carbetocin had a longer effect in similar in-vitro experiments (4). Carbetocin 
has a longer duration of effect because of its considerably longer half-life (up to 6 hours) 
compared with oxytocin (1–8 minutes) (5). 
Oxytocin had the shortest duration of effect; a significant increase in intrauterine pressure 
only occurred during the first 15 minutes after administration in oestrus. In dioestrus, the 
pressure did not increase and instead decreased significantly below baseline after 45 minutes 
until the end of the measuring period. Similarly, intrauterine pressure was elevated for 1–
3 minutes (14) or up to 27 minutes after intravenous administration (27). Oxytocin caused 
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contractions during oestrus but not on day 11 of the cycle in cows (12) or increased uterine 
pressure for 15–20 minutes in oestrus and dioestrus (30). The short duration of effect of 
oxytocin is explained by its short half-life (5). It is possible that in the present study, short-term 
pressure increases may have occurred during dioestrus, but did not affect the mean of the 15-
minute period of measurement. 
PGE2 had the second longest duration of effect in oestrus (60 minutes) as well as in 
dioestrus (45 minutes). In dioestrus, the period of uterotonicity was followed 15 minutes later by 
pressures below baseline. In another study, PGE2 caused a 20-minute increase in uterine 
tonicity at different cycle stages which however was not followed by a decrease below baseline 
in dioestrus, possibly because drug administration was repeated after 30 minutes (29). A 
significant increase in intrauterine pressure lasting 45 minutes also occurred after the 
intravenous administration of 1.25 mg, 2.5 mg and 5 mg PGE2 to dioestrous cows (17, 19). 
The 30-minute increase in intrauterine pressure after PGF2α in oestrous and dioestrous cows 
was shorter than after carbetocin and PGE2. In oestrus, this was followed by a transient 
pressure decrease, after which the pressure increased again. In dioestrus, this was followed by 
a pressure decrease that lasted until the end of the measuring period. Other authors observed 
a pressure increase in dioestrus but not in oestrus (9, 34) or increases at both cycle stages of 
up to 17 minutes and 20 minutes, respectively (27, 29). A significant 30-minute pressure 
increase similar to our study was seen in dioestrous cows, but it was followed by a 90-minute 
plateau, rather than a decrease below baseline (15). The reason for this discrepancy is not 
known. Until now a comparable pressure decrease was only described in one study in cows 
during oestrus and dioestrus and occurred within 30 minutes after administration of 
cloprostenol (29). In our study drops in intrauterine pressure below baseline and the resulting 
negative intrauterine pressures were also seen after PGE2 and oxytocin in dioestrus. Based on 
these finding it may questionable whether the use of these drugs would be beneficial during 
dioestrus. 
The timing of calibration of a pressure catheter is critical for the recording of negative 
pressure. It is plausible that the relaxed uterus adopts a negative pressure after adaption to the 
normal negative pressure in the abdomen, provided that the cervix and vagina form a sufficient 
seal to prevent equalisation of pressure. In the present study, calibration of the transducer was 
achieved before insertion into the uterus and thus, baseline pressure corresponded to 
barometric pressure. This allowed us to record actual absolute negative pressures relative to 
the relatively stable barometric pressure. In contrast, when calibration was achieved some time 
after insertion of the transducer into the uterus, baseline pressure corresponded to intrauterine 
pressure and pressure changes were measured relative to the initial intrauterine pressure (15). 
In that study, negative intrauterine pressures did not occur. Direct comparison of intrauterine 
pressures across various studies was difficult because most authors did not specify the time of 
calibration. 
From a clinical point of view these findings are crucial, because the therapeutic effect of an 
uterotonic drug is not only based on the ability to increase uterine pressure but also to prevent 
a pressure drop below baseline. Based on our 2-hour measurement period, in dioestrus PGE2 
caused pressure increases and decreases of equal length. PGF2α caused a longer period of 
pressure decrease than increase, and the effect of oxytocin was limited to a pressure decrease 
when given in dioestrus. It is therefore possible that these drugs are contraindicated in 
dioestrus when an increase in intrauterine pressure is the goal. Except for oxytocin, the drugs 
used in this study can be expected to cause a transient increase in intrauterine pressure when 
given for the purpose of evacuation of pathological material; however, the relaxation that 
follows the pressure increase could contribute to further pooling of retained material. Studies 
involving cows with metritis and using longer measuring times are needed to investigate the 
therapeutic efficacy of uterotonic drugs. 
 Carbetocin caused the longest-lasting increase in intrauterine pressure, and in dioestrus a 
drop in pressure below baseline did not follow the increase. Carbetocin is therefore the best 
option when the goal of treatment is prolonged uterine contraction. PGF2α causes a short-lived 
pressure increase in dioestrus, but the oestrus period that follows luteolysis is associated with 
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increased uterine tone. In clinical field studies the direct effect of PGF2α on the uterine pressure 
to cure endometritis is controversial (25, 33). However the induction of oestrus through 
luteolysis seems to be beneficial in cows with endometritis after the first month post partum 
(33). Both strategies benefit the evacuation of the uterus and might also complement one 
another. If the therapeutic target is an immediate increase of the intrauterine pressure, 
carbetocin provokes the best direct uterotonic effect in both cycle stages. The effects of the four 
uterotonic drugs on the various uterine segments were similar. The selectively different effects 
of PGE2 on the cervix and the remaining parts of the uterus which are typical of the peripartum 
period of different various species (10, 11, 21, 31) could not be confirmed in dioestrus and 
oestrus. 
Conclusion for practice 
■■■ Compared to the other three uterotonic drugs Carbetocin may be the best option when the 
aim of treatment is an immediate and prolonged uterine contraction. During estrus PGF2α, 
PGE2 and Oxytocin caused a shorter pressure increase, which may useful evacuating 
pathological content from the uterus. However, the subsequent pressure drop below baseline 
could jeopardise this. In contrast to Carbetocin, PGF2α and PGE2 oxytocin caused no 
measurable pressure increase during diestrus.   
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Fig. 1 Microchip precision pressure catheter in the reproductive tract of a cow (pathological preparation). 
The left uterine horn and part of the vagina, but not the uterine body and cervix, have been opened. The 
rubber band sutured to the perineum and tied to the top ring of the catheter is not shown. (A = incised left 
uterine horn, B = cervix, C = partially opened vagina, D = tubing used to fix the pressure catheter in 
place, P1–P4 = measuring points of the pressure catheter in the uterine horn (P5 in the uterine body and 
P6 in the cervix are not visible). 
Abb. 1 Mikrochip-Präzisionsdruckmesskatheter im Reproduktionstrakt einer Kuh (Sektionspräparat). Das 
linke Uterushorn und Teile der Vagina wurden eröffnet, jedoch nicht der Uteruskörper und die Zervix. 
Das am Perineum fixierte und zum Hülsenring gespannte Gummiband ist nicht dargestellt. (A = 
eröffnetes linkes Uterushorn, B = Zervix, C = teileröffnete Vagina, D = Druckkatheter in Fixationshilfen, 
P1–P4 = Messpunkte des Druckkatheters im Uterushorn (nicht sichtbar sind P5 im Uteruskörper und P6 
in der Zervix). 
Fig. 2 Overall intrauterine pressure during dioestrus (green) and oestrus (orange) in eight time periods 
for all drugs combined. (↓ = drug administration; * p < 0.001). 
Abb. 2 Vergleich der Uterusdrücke im Diöstrus (orange) und Östrus (grün) anhand der acht 
Zeitabschnitte unabhängig vom verwendeten Medikament und den Messpunkten im Uterus. (↓ = 
Zeitpunkt der Medikation; * p < 0,001). 
 
Fig. 3 Intrauterine pressure at six measuring points before (time period 1 – baseline) and after 
medication (time period 2–8) in dioestrus for all drugs combined. (Columns with decreasing colour 
intensity correspond to measuring points 1–6; ↓ = drug administration) 
Abb. 3 Vergleich der Uterusdrücke an den sechs Messpunkten vor (Zeitabschnitt 1) und nach 
Medikamentengabe (Zeitabschnitte 2–8) im Diöstrus unabhängig vom applizierten Medikament. (Säulen 
mit abnehmender Farbintensität entsprechen den Messpunkten 1–6. ↓ = Zeitpunkt der Medikation). 
  
14 
 
Fig. 4 Intrauterine pressure at six measuring points before (time period 1 – baseline) and after 
medication (time period 2–8) in oestrus for all drugs combined. (Columns with decreasing colour intensity 
correspond to measuring points 1–6; ↓ = drug administration). 
Abb. 4 Vergleich der Uterusdrücke an den sechs Messpunkten vor (Zeitabschnitt 1) und nach 
Medikamentengabe (Zeitabschnitte 2–8) im Östrus unabhängig vom applizierten Medikament. (Säulen 
mit abnehmender Farbintensität entsprechen den Messpunkten 1–6. ↓ = Zeitpunkt der Medikation) 
 
 
 
Fig. 5 Intrauterine pressure at six measuring points before (time period 1) and after medication (time 
period 3) in dioestrus for all drugs combined. (Columns with decreasing colour intensity correspond to 
measuring points 1–6; * p ≤ 0.05) 
Abb. 5 Vergleich der Uterusdrücke an den sechs Messpunkten zwischen Zeitabschnitt 1 vor der 
Medikation und Zeitabschnitt 3 nach der Medikation im Diöstrus unabhängig vom applizierten 
Medikament. (Säulen mit abnehmender Farbintensität entsprechen den Messpunkten 1–6; * p ≤ 0,05). 
Fig. 6 Intrauterine pressure at six measuring points before (time period 1) and after medication (time 
period 3) in oestrus for all drugs combined. (Columns with decreasing colour intensity correspond to 
measuring points 1–6; * p ≤ 0.05) 
Abb. 6 Vergleich der Uterusdrücke an den sechs Messpunkten zwischen Zeitabschnitt 1 vor der 
Medikation und Zeitabschnitt 3 nach der Medikation im Östrus unabhängig vom applizierten Medikament. 
(Säulen mit abnehmender Farbintensität entsprechen den Messpunkten 1–6; * p ≤ 0,05). 
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Table 1 Intrauterine pressure (mmHg) at six measuring points before (time period 1) and after medication 
(time period 2–8) for all drugs combined. (Superscript numbers indicate measuring points with 
significantly different pressure; p < 0.05). 
Tab. 1 Uterusdrücke (mmHg) an den sechs Messpunkten vor (Zeitabschnitt 1) und nach der Applikation 
der Medikamente (Zeitabschnitt 2–8). (Hochgestellte Ziffern markieren Messpunkte mit signifikant 
differierenden Druckwerten; p < 0,05). 
Table 2 Intrauterine pressure (mmHg) before (time period 1) and after medication (time periods 2–8). 
(Superscript numbers indicate time periods with significantly different pressure. Letters in bold indicate a 
significant pressure increase, letters in italic indicate a significant pressure decrease compared with 
baseline pressure (p ≤ 0.05). 
Tab. 2 Uterusdrücke (mmHg) vor (Zeitabschnitt 1) und nach der Applikation der Medikamente 
(Zeitabschnitt 2– 8). (Hochgestellte Ziffern markieren Messpunkte mit signifikant differierenden 
Druckwerten. Signifikante Druckanstiege sind durch Fettdruck hervorgehoben, signifikante Druckabfälle 
durch Kursivdruck; p ≤ 0,05). 
 
Table 1 
 
 
Table 2 
 
  
Carbetocin Oxytocin Prostaglandin E2 Prostaglandin F2α
Dioestrus Oestrus Dioestrus Oestrus Dioestrus Oestrus Dioestrus Oestrus
2.8 ± 5.492345 14.6 ± 15.4523456 5.3 ± 10.095678 14.5 ± 13.393 -1.0 ± 5.51234678 9.5 ± 10.082345 5.6 ± 11.33235678 11.3 ± 13.71237
6.9 ± 9.551678 20.3 ± 19.931348 3.3 ± 8.47378 17.2 ± 18.16 13.7 ± 15.351345678 32.9 ± 19.451345678 8.8 ± 10.59145678 15.6 ± 15.521
8.0 ± 6.8315678 23.7 ± 21.2112678 6.6 ± 9.8925678 19.7 ± 17.56158 6.4 ± 9.751245678 18.7 ± 16.581245678 8.9 ± 9.64145678 15.1 ± 17.711
6.5 ± 8.1015678 25.1 ± 20.13125678 4.2 ± 9.34578 20.8 ± 18.325678 1.6 ± 8.551235678 13.3 ± 18.80123 4.0 ± 7.9223678 15.0 ± 17.86
4.8 ± 8.21134678 20.6 ± 21.221478 0.7 ± 7.511348 16.4 ± 16.0534 -0.9 ± 6.69234678 15.4 ± 19.751236 2.7 ± 10.1112378 14.5 ± 17.27
2.2 ± 9.252345 18.7 ± 18.621234 0.9 ± 8.811378 16.4 ± 15.064 -4.5 ± 8.051234578 10.4 ± 20.99235 1.9 ± 10.2012378 15.1 ± 19.63
2.7 ± 7.552345 17.6 ± 18.05345 0.4 ± 10.70123468 15.3 ± 17.704 -6.6 ± 7.05123456 13.1 ± 19.3423 -0.9 ± 9.87123456 15.1 ± 19.821
0.8 ± 7.582345 15.4 ± 19.552345 -1.7 ± 8.281234567 14.7 ± 14.3334 -6.3 ± 7.87123456 12.2 ± 20.4923 -2.4 ± 10.48123456 12.8 ± 15.64
5
6
7
8
Time
period
1
2
3
4
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Vorschlag zur Neugliederung 
Material and methods 
Animals 
Six multiparous Swiss Braunvieh cows that were at least 8 weeks in milk and between 5 and 16 
years old from a university-owned research farm were used. The cows had to be assessed 
healthy in the clinical and gynaecological examinations before they were included in the 
experiment. 
Study design 
Each of the six cows underwent one pressure measurement with each of four experimental 
drugs during oestrus and during dioestrus for a total of 48 measurements.  
Determination of cycle stage 
To determine the cycle stage, the ovaries of the cows were examined transrectally once daily 
using B-mode sonography until ovulation was detected, which was defined as the first day that 
a follicle was no longer visible on the sonograms (day 0). After ovulation, the daily examinations 
were continued to verify the cycle stage. 
A corpus luteum with a diameter ≥ 23 mm combined with a plasma progesterone 
concentration > 1 ng/ml was defined as dioestrus (7, 8). A corpus luteum with a diameter < 23 
mm combined with a plasma progesterone concentration ≤ 1 ng/ml and one or several follicles 
with a diameter ≥ 12 mm was defined as oestrus. 
For determination of plasma progesterone concentration, 10 ml blood was collected from a 
jugular vein into a lithium heparin tube (Sarstedt, Nümbrecht, Germany) and centrifuged. The 
harvested plasma was stored at –18 °C until analysis. Progesterone was measured at the 
Endocrinology Laboratory at the Clinic for Obstetrics, Gynaecology and Andrology for Large 
and Small Animals and Ambulatory Field Service, Justus-Liebig-University, Giessen, Germany 
using a radioimmunoassay (24). 
Application of uterotonic drugs 
Experimental drugs included carbetocin (LongActon®, Vital, Switzerland), oxytocin 
(Physovetin®, Streuli Pharma, Switzerland), prostaglandin E2 (Dinoproston, Myoton E2®, 
Graeub, Switzerland) and prostaglandin F2α (Dinoprost, Dinolytic®, Zoetis, Switzerland). The 
dosages and routes of administration were chosen according to the manufacturers’ 
recommendations and were as follows: 30 IU for oxytocin, intramuscularly (i. m.); 0.35 mg for 
carbetocin, i. m.; 25 mg for prostaglandin F2α, i. m.; and 2.5 mg for prostaglandin E2 2.5 mg, 
intravenously into a jugular vein. The triceps muscle of the forearm was used for intramuscular 
injections. 
Oxytocin or carbetocin were tested on day 10 and PGE2 or PGF2α after a wash-out period of 
48 hours (day 12) of the same cycle. Oxytocin or carbetocin was then tested on the first day of 
the next oestrus, and PGE2 or PGF2α after a wash-out period of 24 hours to ensure that both 
measurements were carried out during the same oestrus. The same course of measurements 
was done starting with the second peptide hormone (oxytocin or carbetocin) and the second 
prostaglandin (PGE2 or PGF2α). 
Pressure catheter and fixation 
The pressure catheter was a Gastrobar® microchip precision pressure catheter with six semi-
conductor pressure sensors (microtransducers) custom-made for this study (Raumedic, 
Münchberg, Germany). The probe had an average diameter of 3.5 mm and the first pressure 
sensor (P1) was 2 cm from the tip of the probe (Fig. 1). The remaining pressure sensors (P2 to 
P6) were located at 5-cm intervals so that the sixth sensor was 27 cm from the tip of the probe. 
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The microchip precision pressure catheter was introduced into a uterine horn via a sheath 
(modified Detlef biopsy instrument reaching from the handle to the external cervical os; Fig. 1). 
After placement of the pressure catheter (A, green catheter visible in the opened uterine horn 
and at the caudal end of the sheath) a piece of plastic tubing (D, custom-made from the sheath 
of a swabbing instrument) with the same length as the sheath and with a slit along its entire 
length was clipped onto the catheter piece by piece and slid towards the cervix. The caudal end 
of the tubing rested against the two rings at the caudal end of the sheath, which was attached 
to the perineal tissue with an elastic band (not shown in Fig. 1). The tubing served to fix the 
pressure catheter in place. A 20-mm bulb attached to the tip of the stealth was lodged against 
the external cervical os by force of the elastic perineal attachment and kept the tube and 
catheter from entering the cervix. The premeasured position of the 77-cm mark of the pressure 
catheter at the caudal end of the catheter ensured that the most caudally located measuring 
point P6 was located 4 cm cranial to the bulb-end of the plastic tubing in the cervix. The 
pressure data were transmitted to an attached measuring unit (Ellipse, Andromeda, 
Taufkirchen/Potzham, Germany) and from there to a laptop. The software AUDACT 
(Andromeda) was used to store and analyse the data. 
Pressure measurement procedure and data processing 
The pressure catheter was calibrated to barometric pressure and set to 0 before intrauterine 
placement. The cows were allowed 20 minutes to adapt to the catheter. At the beginning of 
every measurement (four in dioestrus and four in oestrus per cow), recordings of the 
physiological uterine pressure were carried out for 15 minutes (baseline measurement). The 
test drug was then given and the pressure recorded for another 105 minutes. Measuring 
artefacts defined as impacts on the pressure sensors that were not related to changes in 
myometrial tone such as urination, defecation, coughing, vocalisation or straining to expel air 
from the vagina were noted. 
Heart and respiratory rates and possible side effects were recorded before the start of the 
experiment, 10 minutes after the start of pressure recordings and 5, 30, 60 and 120 minutes 
after administration of the test drug. 
Each measuring point of the pressure catheter yielded data sets with 20 pressure readings 
per second. These data sets were transferred to an Excel spread sheet (Microsoft, Wallisellen, 
Switzerland) and means were calculated for a 15-minute period (minutes 15–29, referred to as 
baseline) before and seven 15-minute periods (minutes 31–45, 46–60, 61–75 etc.) after drug 
administration. The readings from the six measuring points were used for comparison of the 
pressure in different uterine segments, and the means of all six measuring points were used for 
comparison of the overall pressure. In case of artefacts, a software program (AUDACT, 
Andromeda) was used to delimit and eliminate the affected recordings, and the means were 
calculated for the remaining data of the respective 15-minute period. 
Endpoints 
Oestrous cycle-related changes in overall uterine pressure were analysed using the means of 
the eight time periods during oestrus and dioestrus for all drugs combined. 
Differences in pressure between individual measuring points were analysed for all eight time 
periods during dioestrus and oestrus for all drugs combined. Differences in pressure between 
individual measuring points were analysed during oestrus and dioestrus for each drug by 
comparing time periods 1 and 3. Time period 3 (i. e., the second after medication) was 
associated with the greatest pressure increase for all pressure points. 
The duration of effect of each drug was determined during dioestrus and oestrus by 
comparing the mean overall pressure during time period 1 with the pressures during time 
periods 2 to 8. This allowed determination of the duration of effect for each drug with an 
accuracy of 15 minutes. 
Statistics 
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The mean uterine pressures recorded at the eight measuring periods were analysed using 
StatView Version 5.0 (SAS Institute, Cary, USA). The Shapiro-Wilk test was employed to test 
the data for normal distribution. Because all data were normally distributed, they were reported 
as mean ± standard deviation. Including the individual differences in the statistical models 
differences in pressure between time periods were analysed for both cycle stages separately or 
combined for each drug using a paired t-test. 
Student’s t-test for paired samples was used to analyse differences in mean overall pressure 
at all time periods between oestrus and dioestrus for each drug separately and for all drugs 
combined, to analyse differences in mean pressure at the individual measuring points and in 
each time period for all drugs and both cycle stages combined and to analyse differences in 
mean pressure recorded at the different measuring points between time periods 1 and 3. A p-
value ≤ 0.05 was considered significant. 
This study was approved by the Committee for the Permission of Animal Experimentation of 
the Canton of Zurich (04/2007). 
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Vorschlag zur Neugestaltung von Abbildung 3 und 4. Die ausgewählten Farben korrespon-
dieren mit den in der Zeitschrift verwendeten Farben. So erscheinen die Abbildungen nicht zu 
bunt. Die Unschärfe der Abb. hier resultiert daraus, dass es sich um einen eingefügten Screen-
shot handelt. 
Fig. 3 Intrauterine pressure at six measuring points before (time period 1 – baseline) and after 
medication (time period 2–8) for all drugs combined in dioestrus (a) and oestrus (b). (Columns with 
decreasing colour intensity correspond to measuring points 1–6; ↓ = drug administration). 
Abb. 3 Vergleich der Uterusdrücke an den sechs Messpunkten vor (Zeitabschnitt 1) und nach 
Medikamentengabe (Zeitabschnitte 2–8) im Diöstrus (a) und Östrus (b) unabhängig vom applizierten 
Medikament. (Säulen mit abnehmender Farbintensität entsprechen den Messpunkten 1–6. ↓ = Zeitpunkt 
der Medikation). 
 
 
 
 
